Emicizumab in Severe Hemophilia A: Clinical and Patient Determinants of Transition Within a Standardized Program
{{output}}
Background: Emicizumab (Hemlibra) became more accessible for Canadians in 2021, when Canadian Blood Services approved it under formulary for prophylaxis in patients with severe hemophilia A (PWHA) without inhibitors. This offered... ...
